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Abstract. Oral cancer cells have a significantly augmented 
nuclear factor-κB (NF-κB) activity and the inhibition of this 
activity suppresses tumor growth. Bortezomib is a protea-
some inhibitor and a drug used for molecular-targeted therapy 
(targets NF-κB). In this study, we investigated whether bort-
ezomib would be effective as an inhibitor of proliferation and a 
radiosensitizer for the treatment of oral cancer. We demonstrate 
that bortezomib inhibits NF-κB activity and cell prolifera-
tion. The combined treatment with bortezomib and radiation 
(RT) suppressed NF-κB activity and cell growth in vitro and 
in vivo compared with RT treatment alone. To investigate the 
mechanisms by which bortezomib suppresses tumor growth, 
the expression of signaling molecules downstream of NF-κB 
were examined by ELISA. The combined treatment signifi-
cantly inhibited the radiation-induced production of angiogenic 
factors and decreased the number of blood vessels in the tumor 
tissues. Although the expression of anti-apoptotic proteins was 
upregulated by RT, bortezomib downregulated the RT-induced 
expression of these proteins. Moreover, the expression of 
cleaved poly(ADP-ribose) polymerase in vitro and in vivo was 
enhanced by bortezomib, indicating that bortezomib inhibits 
tumor growth by inducing apoptosis. This study clearly demon-
strates that bortezomib significantly inhibits tumor growth and 
that the combined treatment with bortezomib and RT results 
in a significant inhibition of tumor growth. The mechanisms 
underlying the inhibition of tumor growth by bortezomib 
include the suppression of angiogenesis and the induction 
of apoptosis. A novel molecular targeting therapy including 
bortezomib may be effective in the treatment of oral cancer by 
suppressing NF-κB activity.
Introduction
The 5-year survival rates of advanced stages (stage III and IV) 
in oral squamous cell carcinoma (OSCC) have not improved. 
Treatment options are limited and patients with oral cancer 
frequently fail to respond to standard therapies. However, recent 
advances in the understanding of the molecular events under-
lying the initiation, progression and metastatic spread of oral 
cancer may lead to the discovery of novel therapeutic targets. 
Despite the fact that concurrent chemoradiation therapy marked 
an improvement in disease control and survival, the resistance 
of cancer cells to radiation remains a major therapeutic issue. 
Based on these considerations, we investigated potential molec-
ular targets for the improvement of treatment in oral cancer.
Nuclear factor-κB (NF-κB) represents a family of dimeric 
transcription factors that are characterized by a 300-amino acid 
region, termed the Rel homology domain (1,2). In unstimulated 
cells, inhibitor of NF-κB (IκB) proteins localize with NF-κB 
dimers in the cytoplasmic compartment by masking the nuclear 
localization sequences of NF-κB subunits (1,2). The activation 
of NF-κB occurs via various stimuli, such as inflammatory 
cytokines, or the receptors which initiate the signal transduction 
cascade leading to activation of the IκB kinase (IKK) complex 
(IKKα, β and γ) (3-5). Following the activation of IKK, the IKK 
complex phosphorylates IκB at serine residues, which target 
IκB for ubiquitination and degradation by a proteasome-depen-
dent pathway (1-5). Following IκB degradation, NF-κB allows 
nuclear accumulation that promotes sequence-specific DNA 
binding and the transcriptional activation of target genes. Akt, 
which functions downstream of Ras and phosphatidylinositol 
3'-kinase (PI3K), control the transcriptional activation through 
a mechanism that is dependent on IKK function and p65 phos-
phorylation.
NF-κB plays a crucial role in the control of cell growth, differ-
entiation, apoptosis, inflammation, stress response and many 
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other physiological processes (3-5). NF-κB has been reported 
to selectively enhance the expression of pro-inflammatory 
cytokines, such as interleukin (IL)-1α, IL-6 and IL-8, as well as 
the expression of degradative enzymes, such as matrix metal-
loproteinase (MMP)-9 (6-13), supporting the notion that NF-κB 
significantly contributes to tumor progression and metastasis in 
various types of cancer, including OSCC (14,15). Indeed, it has 
been reported that IL-1α and IL-6 are associated with increased 
the growth of OSCC (13) and that the production of IL-6, IL-8, 
granulocyte-macrophage colony-stimulating factor (GM-CSF) 
and vascular endothelial growth factor (VEGF) is associated 
with the increased angiogenesis and metastasis of SCC (6-13). In 
addition, it is of particular interest that the expression of IL-1α, 
IL-6, IL-8, GM-CSF, VEGF and MMP-9 has been shown to be 
positively regulated by NF-κB (6-13). Therefore, the inhibition 
of NF-κB activity may constitute a promising approach in the 
treatment of oral cancer.
A number of human solid tumor cell lines, multiple 
myeloma, prostate cancer, leukemia, thyroid cancer and breast 
cancer, display an increased level of nuclear NF-κB activity 
or NF-κB transcriptional activity (16-23). We have previously 
shown that human head and neck cancer cells have a signifi-
cantly enhanced activity of NF-κB as compared to their normal 
counterparts, suggesting that NF-κB plays an important role in 
the development of oral cancer (14). We have also demonstrated 
that the production of angiogenic and growth factors in response 
to radiotherapy and chemotherapy is one of the principal mech-
anisms of inducible radioresistance and chemoresistance in 
human oral cancers, and that the introduction of super-repressor 
IκBα cDNA into human OSCC cells constitutively inhibits the 
nuclear translocation of NF-κB, causing a drastic decrease in 
tumorigenicity, partly as a result of the downregulation of the 
expression of angiogenic factors and the acquirement of sensi-
tivity to radio- or chemotherapy (15). We have also suggested 
that NF-κB may be an important therapeutic target for the 
improvement of conventional radiotherapy in OSCC.
A key step in NF-κB activation involves the 26S protea-
some. The 26S proteasome can be inhibited by a proteasome 
inhibitor, bortezomib (formally PS-341, or Velcade), which is a 
dipeptidyl boronic acid that inhibits the 26S proteasome (24). 
Bortezomib has been clinically approved for the treatment of 
refractory multiple myeloma and mantle cell lymphoma world-
wide. A number of clinical trials have investigated the efficacy 
of bortezomib for the treatment of solid tumors (25-39).
We hypothesized that the inactivation of NF-κB by bort-
ezomib prior to the treatment of cancer cells with radiation 
(RT) would sensitize cells to apoptosis, resulting in a more 
profound cancer cell killing effect. In this study, we investigated 
our hypothesis by evaluating the effects of bortezomib and the 
combination of bortezomib and RT on tumor growth, apoptosis, 
the expression of NF-κB-regulated genes and NF-κB activation 
in oral cancer cells, as well as the mechanisms involved.
Materials and methods
Cell lines. Three human OSCC cell lines (B88, BHY and HNt) 
previously established in our laboratory were used in the present 
study (15). These cells were cultured in DMEM supplemented 
with 10% fetal bovine serum (FBS) and 1X antibiotic̸antimycotic 
(Invitrogen Life Technologies, Carlsbad, CA).
In vitro cell growth assay. Cells (5x103 cells per well) were 
seeded on 96-well plates. Twenty-four hours later, the cells 
were treated with or without bortezomib, which was supplied 
by Millennium Pharmaceuticals, Inc. (Cambridge, MA), for 
72 h. In parallel, cells were exposed to RT by a Hitachi Medical 
MBR-1505R2 X-ray generator (Tokyo, Japan). After the 
72 h-treatment with or without bortezomib and̸or RT, 10 µl of 
5 mg̸ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) (Sigma-Aldrich, St. Louis, MO) were added 
to each well and the cells were incubated for 4 h. The blue 
dye absorbed by the cells was dissolved in dimethyl sulfoxide 
(100 µg̸ml) and the absorbance was measured with a spectro-
photometer at 540 nm. All assays were run in triplicate.
Luciferase assay. The luciferase assay was performed using the 
transfected cells. A reporter plasmid (0.4 µg) consisting of the 
NF-κB responsive elements (BD Biosciences, San Jose, CA) 
and the luciferase gene was transfected into 3 cell clones using 
Effectene transfection reagent (Qiagen, Hilden, Germany). 
G418-resistant colonies were isolated, the luciferase activity was 
measured and 3 cell lines were established (B88-luc, BHY-luc 
and HNt-luc) for use in the following experiments. Cell lysates 
or tissue extracts were subjected to a luciferase assay using a 
luciferase assay system (PicaGene, Toyo-Ink, Tokyo, Japan) 
and a luminometer (LUMAT LB9507; Perkin-Elmer Life and 
Analytical Sciences). All assays were run in triplicate.
In vivo tumor growth assay. The tumorigenic potential of 
the cancer cells was assessed by inoculation of the cells into 
5- to 6-week-old female athymic BALB̸c nude mice (CLEA 
Japan Inc., Osaka, Japan). Cells (5x106 cells) were injected 
subcutaneously (s.c.) into the backs of 5 mice. When tumors 
reached 50-100 mm3 in volume, they were either exposed to RT 
(1.5 Gy̸day, 3 times̸week), or treated with bortezomib [0.1 mg̸kg, 
by intravenous (i.v.) injection, 3 times̸week] for 2 weeks. Tumors 
at the inoculation site were examined 3 times̸week and the tumor 
size was measured. Tumor volume was calculated according to 
the formula: (largest diameter)2 x (smallest diameter) x0.5. The 
mice were maintained under pathogen-free conditions and 
were handled in accordance with the Guidelines for Animal 
Experimentation of Tokushima University.
Electrophoretic mobility shift assay (EMSA). The probe 
consisted of NF-κB-specific double-stranded oligonucleotides 
with the sequence 5'-AGTTGAGGGGACTTTCCCAGGC-3' 
containing the κB site from the κ light chain enhancer in B cells. 
Oligonucleotides were end-labeled with [γ-32P]ATP using poly-
nucleotide kinase and unincorporated [γ-32P]ATP was removed 
by Sephadex G-50-packed spin columns (Pharmacia Biotech, 
Uppsala, Sweden). Nuclear extract preparations and EMSA 
were carried out as described previously (15).
Western blot analysis. After the cells were either treated 
with bortezomib or exposed to RT, they were collected and 
lysed. B88 cells (5x106) were subcutaneously inoculated into 
the backs of nude mice. Tumor-bearing nude mice received 
an i.v. administration of bortezomib alone (0.1 mg̸kg̸day, 
3 days), RT alone (1.5 Gy̸day, 3 days), or both in combination. 
Twenty-four hours after exposure to RT or the i.v. administra-
tion of bortezomib, the tumors were excised and the protein 
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was extracted. Whole-cell lysates were subjected to electropho-
resis on 10% SDS-polyacrylamide gels, then transferred onto 
nitrocellulose membranes. The membranes were incubated 
with the following antibodies: rabbit polyclonal antibodies 
against Akt, phospho-Akt, IKKα̸β, phospho-IKK α̸β, IκBα, 
phospho-IκBα, p65, phospho-p65, FLICE-like inhibitory 
protein (FLIP) and tubulin were obtained from Cell Signaling 
Technology, Inc. (Beverly, MA). Mouse monoclonal antibodies 
against cellular inhibitor of apoptosis (cIAP)1 and X-linked 
inhibitor of apoptosis protein (XIAP) were obtained from 
R&D Systems (Minneapolis, MN), rabbit polyclonal antibody 
against cIAP2 was from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA), poly(ADP-ribose) polymerase (PARP) was from 
BD Biosciences and mouse monoclonal antibody against 
β-actin was from Sigma-Aldrich. After intervening rinses with 
PBS(-), the antibody was detected using a chemiluminescence 
western blotting kit (Amersham, Tokyo, Japan) according to the 
manufacturer's instructions.
Enzyme-linked immunosorbent assay (ELISA) for quantitative 
determination of IL-6, IL-8 and VEGF. The levels of IL-6, 
IL-8 and VEGF in the tumor tissues from the untreated control 
or from the bortezomib-treated or RT-exposed cells were 
measured by a microtiter-based sandwich enzyme immuno-
assay system, which is commercially available and specifically 
estimates the total amount of these factors. After extirpation 
of tumors, extracted protein samples were subjected to ELISA 
using immunoassay kits for IL-6, IL-8 and VEGF (BioSource 
International, Camarillo, CA).
Immunohistochemistry and quantification of blood vessels. 
The tumors were excised, fixed in formalin and embedded in 
paraffin. Sections were dewaxed in xylene and rehydrated in 
graded ethanols according to standard procedures. Antigen 
retrieval was performed by incubating the sections immersed 
in 10 mM citric acid in a microwave oven at 100˚C. An 
anti-factor VIII antibody (DAKO Corporation, Carpinteria, 
CA) was used as the primary antibody. Negative controls for 
each material were processed in the same manner, using a 
non-immunized rabbit IgG (DAKO) instead of the primary 
antibody. The average number of factor VIII-positive vessels 
was determined from 3 areas (x200) of the highest vascular 
density in a section. All histological analyses were carried out 
using blinded tumor samples.
Localization of p65 protein by fluorescence staining. Cells 
grown on plain coverslips were fixed in 4% paraformamide 
and incubated with rabbit anti-human p65 antibody. The 
coverslips were then washed and the cells were incubated 
with fluorescence-conjugated donkey anti-rabbit IgG. The 
coverslips were mounted and observed under a fluorescence 
microscope.
RNA isolation and quantitative real-time RT-PCR. When the 
cells reached subconfluence in culture, they were exposed to 
RT (15 Gy) with or without bortezomib (5 nM). Forty-eight 
hours later, total RNA was extracted using TRIzol reagent 
(Invitrogen Life Technologies). The cDNA was synthesized 
from 5 mg of total-RNA using an Advantage cDNA PCR kit 
(Invitrogen Life Technologies). For quantitative real-time PCR, 
equal aliquots of cDNA were amplified according to the manu-
facturer's TaqMan universal (50 ml) PCR master mix protocol 
using RT-PCR ABI PRISM 7000 (Applied Biosystems, Foster 
City, CA). The primer set and TaqMan probe used for the 
experiments were included in a TaqMan gene expression assay 
system (cIAP1; Hs00236911_m1, cIAP2; Hs00154109_m1). 
The data were normalized using RT-PCR GAPDH primers 
(Applied Biosystems).
Statistical analysis. Statistical analysis was performed using 
the Mann-Whitney U test; values of p<0.05 were considered to 
indicate statistically significant differences.
Results
Effects of bortezomib on NF-κB activity and tumor growth 
of oral cancer cells on in vitro and in vivo. To determine 
whether bortezomib suppresses the proliferation of human 
oral cancer cells in vitro, we examined the cell proliferation 
using MTT assay. Bortezomib suppressed the proliferation of 
the 3 oral cancer cell lines tested (B88, BHY and HNt) in a 
dose-dependent manner (Fig. 1A). In addition, since the consti-
tutive activation of NF-κB has been associated with the growth 
and survival of cancer cells (16-22), including oral cancer 
cells, we used a luciferase assay to clarify whether bortezomib 
can induce the downregulation of NF-κB activity (Fig. 1B). 
Bortezomib suppressed the NF-κB activity of the 3 cancer cell 
lines in a dose-dependent manner (Fig. 1B). Subsequently, to 
investigate whether bortezomib has an antitumor effect against 
oral cancer cells in vivo, we developed cancer xenografts in 
nude mice using B88 cells. Bortezomib treatment was initi-
ated after the cancer cell implantation and was continued for 
up to 15 days, in accordance with the experimental protocol. 
Animals were sacrificed 16 days after thetumor cell injection 
and the tumors were excised and weighed. The tumor volume 
of bortezomib-treated tumors was significantly smaller than 
that of the untreated controls (Fig. 1C).
Effects of RT on NF-κB binding ability and activity and the 
expression of signaling pathway molecules. The molecular 
mechanisms by which RT affects the NF-κB signaling pathway 
have not yet been elucidated. Thus, to assess the effects of RT 
on NF-κB activity, DNA binding ability and the molecules 
involved in NF-κB signaling pathways, we performed lucif-
erase assay, EMSA and western blot analysis. The luciferase 
assay for NF-κB activity and the DNA binding assay for NF-κB 
in nuclear extracts from the cancer cells showed that RT signifi-
cantly induced NF-κB activity in a dose- and a time-dependent 
manner (Fig. 2A and B). Since the Akt pathway is an upstream 
signal of NF-κB activation, the altered regulation of the path-
ways has been suggested to lead to the chemoresistance of oral 
cancer cells (27). Thus, we investigated whether or not RT 
phosphorylates Akt, IKK, IκBα and p65. We found that RT 
phosphorylated Akt and IKKα̸β as well as phosphorylating 
and degrading IκBα (Fig. 2C), indicating that the phosphoryla-
tion of these proteins may contribute to the chemoresistance of 
oral cancer cells.
Effects of bortezomib on the NF-κB activity induced by RT, the 
expression of IκBα and localization of p65 in oral cancer cells. 
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To further confirm the effect of bortezomib on NF-κB activity 
induced by RT, we analyzed the expression of IκBα, the local-
ization of p65 and NF-κB activity in cancer cells. The treatment 
of cells with RT resulted in the degradation of IκBα protein 
by 35% compared to the untreated controls (Fig. 3A), whereas 
bortezomib suppressed the RT-induced IκBα degradation by 
62% compared to the untreated controls. We also performed 
immunofluorescence staining of p65. As shown in Fig. 3B, RT 
exposure induced the translocation of the p65 protein from the 
cytoplasm to the nucleus in cancer cells. However, bortezomib 
inhibited the RT-induced nuclear translocation of p65. Finally, 
treatment with bortezomib followed by exposure to RT signifi-
cantly suppressed the RT-induced NF-κB activity in B88 and 
BHY cells (Fig. 3C). These results indicate that bortezomib 
inhibits RT-induced NF-κB activity in oral cancer cells.
Antitumor effects of bortezomib and enhancement of anti-
tumor effects of RT by bortezomib. We examined the effects of 
bortezomib on the viability of cancer cells (Fig. 4A). To deter-
mine whether or not bortezomib enhances the anticancer effect 
of RT, cell viability was evaluated by MTT assay after 72 h 
of treatment with bortezomib and RT in vitro. The exposure 
of cancer cells to RT after treatment with bortezomib resulted 
in a synergistic effect on growth suppression. On the basis of 
these in vitro findings, we evaluated the antitumor effects of 
bortezomib and RT in vivo. B88 cells were injected s.c. into the 
backs of nude mice and treatment was initiated when the tumor 
volume reached 50-100 mm3. As shown in Fig. 4B, the tumors 
treated with the combination of RT and bortezomib showed 
markedly less growth than the untreated controls, or the tumors 
treated with RT alone, or bortezomib alone.
Figure 1. Bortezomib suppressed NF-κB activity and the proliferation of oral cancer cells. (A) Cells (5x103 cells̸well) were seeded in 96-well plates. After 24 h, 
cells were treated with bortezomib. Seventy-two hours later, in vitro cell growth was evaluated by MTT assay as the percentage of growth. (B) The effects of 
bortezomib on NF-κB activity in B88-luc and BHY-luc cells were investigated by luciferase assay. Cells were seeded in 6-well plates. After 24 h, cells were treated 
with bortezomib for 5 h. The cells were then subjected to luciferase assay. NF-κB activity was evaluated by luciferase assay as the percentage of luciferase activity. 
Results are representative of 3 experiments. (C) Effects of bortezomib on in vivo tumor growth. Left panel, B88 cells (5x106) were injected s.c. into the backs of 
nude mice. Bortezomib was administered by i.v. injection (0.1 or 0.5 mg̸kg̸day) 3 times/week. Tumors at the inoculation site were monitored 3 times/week and 
the tumor size was measured. Right panel, after 3 weeks, the mice were sacrificed and the tumors were excised and weighed. *p<0.05 versus untreated controls.
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Effects of bortezomib on NF-κB activity and the expression 
of IL-6, IL-8 and VEGF protein in tumor tissues. To examine 
whether or not bortezomib suppresses NF-κB activity in oral 
cancer tumor tissues, we investigated the NF-κB activity of 
B88-luc-bearing tumors in nude mice by luciferase assay. 
Our results showed that RT alone significantly increased the 
NF-κB activity compared with the untreated controls (Fig. 5A). 
Bortezomib significantly decreased the NF-κB activity induced 
by RT. Moreover, to clarify the mechanisms of the tumor 
growth inhibition by bortezomib, we investigated the effects of 
bortezomib and RT on the production of IL-6, IL-8 and VEGF 
in B88-bearing tumors in nude mice (Fig. 5B-D). Although 
bortezomib significantly decreased the production of IL-6, IL-8 
and VEGF in the tumors from the nude mice, the production of 
these cytokines was markedly stimulated by RT. Bortezomib 
treatment followed by RT significantly suppressed the produc-
tion of IL-6, IL-8 and VEGF as compared with RT exposure 
alone.
In order to determine whether bortezomib suppresses 
oral tumor growth by inhibiting tumor angiogenesis, we 
examined the microvessel density in oral cancer tissues in 
nude mice using immunohistochemical analysis of factor Ⅷ 
(Fig. 5E). Treatment with bortezomib significantly reduced the 
microvessel density compared with the untreated controls or 
RT alone.
Effects of bortezomib on apoptosis and the expression of 
anti-apoptotic proteins induced by RT. Numerous apop-
tosis-related proteins, including cIAP1, cIAP2, XIAP and 
FLIP, all of which are regulated by NF-κB, have been reported 
to be related to chemoresistance. To determine whether bort-
ezomib mediates its effects by downregulating the expression 
of NF-κB-regulated proteins implicated in anti-apoptosis, we 
examined the effects of bortezomib and RT on the expression 
of cIAP1 and cIAP2 mRNA by quantitative RT-PCR. As shown 
in Fig. 6A and B, real-time RT-PCR revealed that cIAP1 and 
Figure 2. (A) Effects of RT on NF-κB activity in B88-luc, BHY-luc and HNt-luc cells investigated by luciferase assay. Cells were seeded in 6-well plates. After 
24 h, cells were treated with RT for 5 h. The cells were then subjected to luciferase assay. NF-κB activity was evaluated by luciferase assay as the percentage of 
luciferase activity. Results are representative of 3 experiments. *p<0.05 versus untreated controls. (B) EMSA for NF-κB activation in B88 cells after treatment 
with or without RT (15 Gy). The specificity of the complex was confirmed by incubation with a 100-fold excess of unlabeled κB oligonucleotide. Oct-1 served as 
the loading control. (C) After the cells were exposed to RT, they were collected and lysed. The expression of Akt, IKK, IκBα and p65, phosphorylated Akt and 
IKKα̸β and the degradation and phosphorylation of IκBα were examined by western blot analysis. β-actin served as the internal control.
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cIAP2 mRNA expression was statistically increased by RT 
compared with the untreated controls, whereas bortezomib 
did not affect the expression levels of these 2 anti-apoptotic 
proteins. The combination of bortezomib and RT significantly 
reduced the cIAP1 and -2 mRNA expression levels as compared 
to RT alone. To investigate whether the enhanced cytotoxicity 
was due to apoptosis, the cleavage of PARP in cancer cells was 
examined by western blot analysis (Fig. 6C). The expression 
of cleaved PARP was significantly enhanced by the combined 
treatment with bortezomib and RT compared with either 
bortezomib treatment or RT exposure alone. Furthermore, to 
identify the mechanism of tumor growth inhibition, we inves-
tigated the effects of bortezomib and RT on the expression of 
cIAP1, cIAP2, FLIP, XIAP, PARP and caspase-3 in B88 cancer 
tissues in nude mice (Fig. 6D). Our results showed that RT 
enhanced the expression of cIAP1, cIAP2, FLIP and XIAP; 
however, bortezomib downregulated the RT-induced expression 
of these proteins. Furthermore, the augmentation of the effect 
of bortezomib on RT-induced expression was considered to be 
cleaved PARP and the inhibition of the expression of caspase-3 
(Fig. 6D).
Discussion
In this study, we investigated whether or not bortezomib 
would be effective for the treatment of oral cancer. Our results 
showed that bortezomib significantly inhibited NF-κB activity 
and the proliferation of oral cancer cells both in vitro and 
Figure 3. Bortezomib inhibited the activation of NF-κB induced by RT. 
(A) Western blot analysis of IκBα protein levels in B88 cells. B88 cells were 
treated with 5 nM bortezomib and RT (15 Gy). Whole cell fractions extracted 
from untreated cells and treated cells were subjected to SDS-PAGE. IκBα pro-
tein was visualized with an IκBα specific antibody as described in Materials 
and methods. (B) Immunofluorescence staining of p65 protein in oral cancer 
cells. B88 cells were grown on coverslips in a 35-mm dish. After the cells 
were exposed to RT (15 Gy) or treated with bortezomib, they were fixed in 
4% paraformaldehyde and permeabilized with 0.1% Triton X-100. The expres-
sion of p65 protein was located in nuclei stimulated by RT. Arrows show the 
localization of p65 protein in the nuclei. (a) untreated, (b) RT (15 Gy), (c) bort-
ezomib (5 nM) and RT (15 Gy), (d) bortezomib (5 nM) and (e) treatment with 
TNF-α as a positive control. (C) The effects of RT and bortezomib on NF-κB 
activity in B88-luc, BHY-luc and HNt-luc cells were investigated by luciferase 
assay. Cells were seeded in 6-well plates. After 24 h, cells were treated with RT 
(15 Gy) and bortezomib for 5 h. Then, cells were subjected to luciferase assay. 
NF-κB activity was evaluated by luciferase assay as 100% luciferase activity 
on cells treated with RT only. Results are representative of 3 experiments. 
*p<0.05 versus untreated controls.
Figure 4. Effects of bortezomib and RT on tumor growth in vitro and in vivo. 
(A) Cells (5x103 cells̸well) were seeded in 96-well plates. After 24 h, cells were 
either treated with bortezomib (10 nM) or exposed to RT (7.5 Gy). Seventy-two 
hours later, in vitro cell growth was evaluated by MTT assay as the percentage 
of growth. *p<0.05. (B) Role of bortezomib and RT in in vivo tumorigenicity 
of B88 cells. Cells (5x106) were inoculated into the backs of nude mice (n=5). 
When the tumors reached 50-100 mm3 in volume, the mice were either 
treated with bortezomib (0.1 mg̸kg̸day, i.v., 3 times̸week) or exposed to RT 
(1.5 Gy̸day, 3 times̸week) for 2 weeks. Tumor diameters along 2 orthogonal 
axes were recorded and tumor volume was calculated by assuming a spherical 
shape of the tumor 3 times a week. Tumor volume was recorded as the mean 
volume for each treatment group (n=5). Bars represent the mean ± SD. *p<0.05 
versus untreated controls. The images on the right represent the excised tumors.
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in vivo. The combined treatment of bortezomib and radiation 
suppressed NF-κB activity and tumor growth in vitro and 
in vivo as compared to radiation treatment alone. To investigate 
the mechanisms of tumor growth suppression by bortezomib, 
we examined the expression of NF-κB downstream signaling 
molecules, such as IL-6, VEGF, IL-8, cIAP1, cIAP2, XIAP 
and FLIP. The results showed that these molecules were 
significantly inhibited by treatment with bortezomib. Thus, our 
present study clearly demonstrates that bortezomib significantly 
inhibits tumor growth by the downregulation of NF-κB and that 
the combined treatment with bortezomib and RT suppresses 
tumor growth when compared with radiation treatment alone. 
The mechanisms underlying the tumor growth inhibition by 
bortezomib were shown to be the suppression of angiogenesis 
via the inhibition of IL-8 and VEGF production, as well as the 
induction of apoptosis in cancer cells.
Several cultured human solid tumor cell lines demon-
strate increased nuclear NF-κB activity and increased NF-κB 
transcriptional activity. NF-κB activity is also activated in 
oral cancer, multiple myeloma, prostate, thyroid and breast 
cancer (17-22). We, as well as others, have previously shown that 
human oral cancer cells have a significantly enhanced NF-κB 
activity compared to their normal counterparts, suggesting 
that NF-κB plays an important role in the development of 
oral cancer (14-17). It has been reported that enhanced NF-κB 
activity in many human solid tumors may be due to the augmen-
tation of IKK activity (14). Increasing evidence indicates that 
the blockade of NF-κB pathways represents a particularly 
promising strategy for the development of novel and selective 
anticancer therapies (17-24). However, the possible mechanisms 
by which the suppression of NF-κB activity in cancer cells 
overcomes the resistance to conventional treatments, such as 
RT and chemotherapy, remain unknown. Thus, to better under-
stand the mechanism by which NF-κB suppression enhances 
sensitivity to radio- and chemotherapy, we focused our attention 
on the effect of NF-κB inhibition on RT- and 5-FU-induced 
Figure 5. Effects of bortezomib on NF-κB activity, the expression of IL-6, IL-8 and VEGF protein and angiogenesis of tumor tissue. B88 or B88-luc cells (5x106) 
were subcutaneously inoculated into the backs of nude mice. Tumor-bearing nude mice received either an i.v. administration of bortezomib (0.1 mg̸kg̸day, 
3 days), RT (1.5 Gy̸day, 3 days), or a combination of bortezomib with RT. Twenty-four hours after the treatment, the tumors were excised and the protein 
was extracted. Samples were subjected to (A) luciferase assay for NF-κB activity and ELISA assay for (B) IL-6, (C) IL-8 and (D) VEGF protein. The excised 
tumors were fixed and applied to immunohistochemical staining of factor VIII. (E) The factor VIII-positive vessels in 5 microscopic fields of the highest 
vascular density were counted. *p<0.05.
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expression of IL-6 and IL-8 in human oral carcinoma cells, 
both of which contribute to tumor growth and angiogenesis 
and are regulated by NF-κB (14,15). Our results showed that 
the consistent inhibition of NF-κB activity in human OSCC 
caused a marked reduction in tumorigenicity through the down-
regulation of IL-1α, IL-6, IL-8, VEGF and MMP-9, and that 
the NF-κB-suppressed B88 cells acquired sensitivity to radio- 
and chemotherapy via the inhibition of RT- and 5-FU-induced 
production of IL-6 and IL-8 (16). Since it has previously been 
shown that several oral cancer cell lines, including B88 cells, 
express high levels of NF-κB activity (17-24), NF-κB would 
be an important therapeutic molecular target for improvement 
of conventional radio- and chemotherapy outcomes of patients 
with OSCC.
A number of methods have been reported as potential 
therapeutic strategies for targeting NF-κB in cancer treatment. 
Small interfering RNAs (siRNAs) (23) or decoy oligonucle-
otides blocking NF-κB protein synthesis (26) or DNA binding 
have been developed as experimental tools to examine the 
role of this factor in various models (15,25). A number of 
studies have suggested that blocking the genes induced by 
NF-κB through these molecular approaches may have an 
antitumor effect in vivo. As novel anti-NF-κB agents, protea-
some inhibitors (MG132, lactacystin, or bortezomib), IκBα 
inhibitors (DHMEQ) and IKK inhibitors (PS-1145) have all 
been proposed (17,19,28). Since bortezomib is the only drug 
currently under clinical development, we chose it for the inves-
tigation of its anticancer effects in this study.
Figure 6. Effects of bortezomib on apoptosis and the expression of anti-apoptotic proteins induced by RT. Quantitative analysis of (A) cIAP1 and (B) cIAP2 
mRNA transcription in B88 cells. RT-PCR products were quantitatively analyzed using an ABI 7000 sequence detection system. The data are shown as the 
ratio of the GAPDH-normalized fold change in the PCR product in bortezomib-treated or RT-exposed cells to the GAPDH-normalized amount of the PCR 
product in untreated cells. *p<0.05. (C) Western blot analysis of PARP cleavage in cancer cells treated with either bortezomib (5 nM) or RT (15 Gy), or the 
combination with bortezomib and RT. Whole-cell fractions extracted from the cells were subjected to SDS-PAGE. The molecular weights of uncleaved and 
cleaved PARP were 112 and 29 kDa, respectively. (D) B88 cells (5x106) were subcutaneously inoculated into the backs of nude mice. Tumor-bearing nude mice 
received either an i.v. administration of bortezomib (0.1 mg̸kg̸day, 3 days), RT (1.5 Gy̸day, 3 days), or a combination of bortezomib and RT. Twenty-four hours 
after the treatment, the tumors were excised and the protein was extracted. Samples were subjected to western blot analysis. The expression of cIAP1, cIAP2, 
FLIP, XIAP, caspase-3 and cleaved PARP was examined.
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Although bortezomib significantly inhibited the NF-κB 
activity in oral cancer cells, it did not suppress NF-κB activity 
in the tumor tissues from nude mice (Fig. 5A). Arlt et al (40) 
reported that the autocrine mechanisms of IL-1β induced the 
constitutive activation of NF-κB and decreased the sensitivity 
for the proteasome inhibitor, MG132, in pancreatic cancer 
cells. It has also been found that the NF-kB inhibitory effects 
on the proteasome inhibitor were affected by the constitutive 
activation of NF-κB in various tumors (41-43). As B88 cells 
do not have autocrine mechanisms of IL-1β or TNF-α, an 
unknown mechanism in vivo disrupted the inhibitory effect of 
NF-κB activity by bortezomib.
Our data showed that RT induced the activity of NF-κB 
through the PI3K̸AKT-IKK pathway, which led to the phos-
phorylation and degradation of IκBα. Bortezomib inhibits 
RT-induced NF-κB activation by suppressing the degrada-
tion of IκBα, thus leading to enhanced radisosensitivity and 
increased apoptosis. Previously, it has been reported that NF-κB 
modulates the pathway of apoptotic responses induced by 
RT (44-46). RT causes many types of DNA damage, including 
DNA double-strand breaks (DSBs). Such DSBs are recognized 
by sensor proteins, which then bind to the damaged region 
and transduce a damaged signal to the components, ataxia 
telangiectasia mutated (ATM). ATM phosphorylates serine-85 
of the NF-κB essential modulator (NEMO) to promote its 
ubiquitin-dependent nuclear export and is also exported in a 
NEMO-dependent manner to the cytoplasm, where it associ-
ates with and causes the activation of IKK. Thus, the regulated 
nuclear shuttling of NEMO is linked to 2 signaling kinases, 
ATM and IKK.
Although RT has been used as an effective anticancer 
modality for the pre- and post-operative treatment of oral cancer, 
it has been demonstrated that RT stimulates the production of 
angiogenic factors; VEGF expression was induced in Lewis lung 
carcinomas in vitro and in vivo after exposure to RT (47-49). In 
addition, the autocrine production of IL-6 by cancer cells and 
the inducible production of VEGF and IL-8 by RT and chemo-
therapeutic agents are considered to be the mechanisms whereby 
cancer cells acquire resistance to radiotherapy (50,51). On the 
basis of these findings, Gorski et al (49) and De Larco et al (50) 
suggested that the inhibition of these molecules by means of an 
antagonistic action using a neutralizing antibody or an angio-
genesis inhibitor (angiostatin) would increase the antitumor 
effects of RT. Karashima et al (6) reported that NF-κB mediated 
angiogenesis and the metastasis of human bladder cancer cells 
through the regulation of IL-8. Huang et al (39) showed that the 
blockade of NF-κB signaling inhibited angiogenesis and the 
tumorigenicity of human ovarian cancer cells by suppressing the 
expression of VEGF and IL-8. In MDA-MB-231 breast cancer 
cells, it has been reported that MG132 inhibited the angiogenesis 
and the expression of VEGF mRNA through the suppression of 
NF-κB activity (39). A novel finding of the present study was 
that bortezomib inhibited tumor growth via the suppression of 
angiogenesis through the inhibition of RT induced production of 
IL-8 and VEGF in oral cancer cells.
Although RT induces cell death via the apoptotic 
pathway, the induction of NF-κB protects cancer cells 
from RT-induced apoptosis and regulates the anti-apoptotic 
protein. On the other hand, we found that an another possible 
mechanism of the effects of bortezomib on the inhibition of 
tumor growth was responsible for the suppression of cIAP1, 
cIAP2, FLIP and XIAP. However, it has been shown that 
NF-κB regulates the many signaling pathways related to cell 
death, including the reactive oxygen species (ROS) pathway 
and c-Jun N-terminal kinase (JNK) pathway, but not the 
caspase pathway (52-54). In future studies, therefore, we aim 
to analyze the effects of bortezomib or RT on these signaling 
pathways.
In conclusion, the present study clearly demonstrates 
that bortezomib significantly inhibits tumor growth and that 
the combined treatment with bortezomib and RT inhibits 
tumor growth as compared to radiation treatment alone. The 
mechanisms underlying the tumor growth inhibitory effects 
of bortezomib include the suppression of angiogenesis via the 
inhibition of IL-8 and VEGF production, as well as the induc-
tion of apoptosis in cancer cells. A novel molecular targeting 
therapy using the proteasome inhibitor, bortezomib, to inhibit 
NF-κB may be effective in the treatment of oral cancer.
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